Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021PRNewsWire • 10/07/21
Enveric Biosciences uses AI platform to identify potential molecules for further drug discoveryProactive Investors • 10/05/21
Bringing Mental Health Pharmacology into the 21st Century: How the Marriage of Enveric Biosciences and MagicMed Industries Could Revolutionize the Way We Treat Mental HealthBenzinga • 10/05/21
Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its 'Psybrary' of Psychedelic Molecular CompoundsPRNewsWire • 10/05/21
Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021PRNewsWire • 09/20/21
MagicMed Industries and Enveric Biosciences finalize merger creating new psychedelic drug discovery firm companyProactive Investors • 09/17/21
Enveric Biosciences Announces MagicMed Industries' Presentations at the Following Investor Conferences in SeptemberPRNewsWire • 09/09/21
MagicMed bidder Enveric Biosciences issues letter to shareholders ahead of mergerProactive Investors • 08/18/21
MagicMed merger partner Enveric says phase 1/2 glioblastoma trial of its synthetic CBD drug has green light from Israeli regulatorsProactive Investors • 07/08/21
Enveric Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for GlioblastomaPRNewsWire • 07/08/21
MagicMed Industries updates on progress ahead of closing of Enveric Biosciences mergerProactive Investors • 07/05/21
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And MoreBenzinga • 06/30/21